Pharmaceutical Industry

Overview

cGMP, US-FDA, and EU-EMA audits require flawless documentation and precise control over potency, yield, and traceability. Plants must balance compliance with lean throughput.

Key Challenges

Issue	Risk
Paper batch records (BMR)	Data errors, audit citations
Long validation cycles	Time to market delays
Cross-contamination	Risk of product recall

Integrated Solutions

Process Transformation – pilot e-BMR and Manufacturing Execution System on one line.
Six Sigma Culture – belt projects on yield variance and blend uniformity.
Operational Efficiency – OEE boosts in granulation, coating, and blister lines.
Financial Governance – cost-to-quality dashboards linking deviations to rupees.

Capability Courses

Drive Highlight

Right-First-Time Batch Drive – 120-day DMAIC program that cut deviations per batch by 45 % and shaved batch-release time by 18 %.

Targeted FAQs

Can we digitise without a full MES rollout?

Start with e-BMR on a pilot line; scale after ROI is proven.

How do Six Sigma toll-gates map to validation stages?

Each DMAIC phase aligns with IQ, OQ, and PQ checkpoints.

Will OEE conflict with cGMP batch integrity?

Efficiency gains come from reduced waiting and changeover—not shortcuts.

Is cloud data storage acceptable to regulators?

Yes, if 21 CFR Part 11 compliance and regional data-residency rules are followed.

How soon can yield improve?

Granulation-stage DMAIC projects often deliver 2–4 % yield gains within 90 days.

Do we need SGS or external validation?

Independent validation is optional; internal QA can approve with proper protocols.